Drug Profile
CTX 101
Alternative Names: AlloCSC 01; CTX-101Latest Information Update: 03 Aug 2018
Price :
$50
*
At a glance
- Originator Coretherapix
- Developer TiGenix
- Class Heart failure therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Myocardial infarction; Ventricular tachycardia